This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Young, J. Articles by Schaison, G. Search for Related Content PubMed PubMed Citation Articles by Young, J. Articles by Schaison, G.

Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions

Service d’Endocrinologie et des Maladies de la Reproduction (J.Y., B.C., P.C., G.S.) and Laboratoire d’hormonologie (S.B.), Hôpital Bicêtre, 94275 Kremlin Bicêtre, France; and ARES Serono (E.L.), CH-1211 Geneva, Switzerland.

Address correspondence and requests for reprints to: Gilbert Schaison, M.D., Service d’Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre, 94275 Kremlin Bicêtre cedex, France. E-mail: gilbert.schaison{at}bct.ap-hop-paris.fr

Experimental data suggest that FSH-stimulated Sertoli cells can enhance LH-induced Leydig cell testosterone (T) production. The function of Leydig and Sertoli cells can be selectively studied by using recombinant human LH (rhLH) and recombinant human FSH (rhFSH) in patients with complete gonadotropin deficiency. The aim of the present study was to assess the secretion of testicular T, estradiol (E₂), and inhibin B and the physiological relevance of the Sertoli-Leydig cell interaction in man. For that purpose, six patients with acquired complete hypogonadotropic hypogonadism received the following treatments for three periods of 1 month in a random order: 1) rhLH, 900 IU/day sc; 2) rhFSH, 150 IU/day sc; and 3) combined rhLH/rhFSH treatments. Each treatment period was separated by a washout period of 15 days. Plasma LH, FSH, T, E₂, and inhibin B were measured before and every 10 days during each treatment. During rhLH administration, mean plasma LH levels rose significantly from 0.4 ± 0.2 IU/L to 11.7 ± 1.2 IU/L (P < 0.01) and plasma FSH levels did not change. rhFSH administration induced a significant increase in plasma FSH levels (from 0.5 ± 0.4 to 12.1 ± 1.4 IU/L; P < 0.01), whereas mean plasma LH levels remained low. Mean plasma E₂ levels were unchanged during rhFSH treatment, but they increased significantly during rhLH from 22 ± 4 to 54 ± 8 pmol/L (P < 0.01) and during rhLH plus rhFSH administration. rhFSH treatment induced a sustained elevation of mean plasma inhibin B levels from 58 ± 13 to 175 ± 25 pg/mL (P < 0.01), similar to the increase occurring during rhFSH plus rhLH administration. In contrast, mean plasma inhibin B levels did not increase during rhLH administration. Finally, a similar and significant increase in mean plasma T levels occurred during both rhLH and rhLH plus rhFSH treatment from 0.9 ± 0.3 to 5.4 ± 0.7 nmol/L (P < 0.01) and from 1.0 ± 0.4 to 6.0 ± 0.9 nmol/L (P < 0.01), respectively. In contrast, during rhFSH treatment mean plasma T levels remained unchanged when compared with baseline. In conclusion: 1) the increase of plasma E₂ induced by rhLH and the absence of effect of rhFSH confirm that Leydig cells are the major site of testicular E₂ production in man; 2) the secretion of inhibin B is increased by rhFSH and not by rhLH, and, thus, Sertoli cells seem to be the main source of inhibin B production; and 3) the increase of plasma T induced by rhLH is not enhanced by rhFSH. These results suggest that the stimulatory effect of FSH on Leydig cell steroidogenesis by a Sertoli cell paracrine factor does not seem to play a major physiologic role in man.

This article has been cited by other articles:

				D.R. Simorangkir, S. Ramaswamy, G.R. Marshall, C.R. Pohl, and T.M. Plant A selective monotropic elevation of FSH, but not that of LH, amplifies the proliferation and differentiation of spermatogonia in the adult rhesus monkey (Macaca mulatta) Hum. Reprod., July 1, 2009; 24(7): 1584 - 1595. [Abstract] [Full Text] [PDF]

				K. Boukari, G. Meduri, S. Brailly-Tabard, J. Guibourdenche, M. L. Ciampi, N. Massin, L. Martinerie, J.-Y. Picard, R. Rey, M. Lombes, et al. Lack of Androgen Receptor Expression in Sertoli Cells Accounts for the Absence of Anti-Mullerian Hormone Repression during Early Human Testis Development J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1818 - 1825. [Abstract] [Full Text] [PDF]

				L. Soriano-Guillen, V. Mitchell, J.-C. Carel, P. Barbet, M. Roger, and N. Lahlou Activating Mutations in the Luteinizing Hormone Receptor Gene: A Human Model of Non-Follicle-Stimulating Hormone-Dependent Inhibin Production and Germ Cell Maturation J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3041 - 3047. [Abstract] [Full Text] [PDF]

				P. Y. Liu, P. Y. Takahashi, P. D. Roebuck, A. Iranmanesh, and J. D. Veldhuis Aging in Healthy Men Impairs Recombinant Human Luteinizing Hormone (LH)-Stimulated Testosterone Secretion Monitored under a Two-Day Intravenous Pulsatile LH Clamp J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5544 - 5550. [Abstract] [Full Text] [PDF]

				J. Young, P. Chanson, S. Salenave, M. Noel, S. Brailly, M. O'Flaherty, G. Schaison, and R. Rey Testicular Anti-Mullerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 724 - 728. [Abstract] [Full Text] [PDF]

				S. B. Rulli, P. Ahtiainen, S. Makela, J. Toppari, M. Poutanen, and I. Huhtaniemi Elevated Steroidogenesis, Defective Reproductive Organs, and Infertility in Transgenic Male Mice Overexpressing Human Chorionic Gonadotropin Endocrinology, November 1, 2003; 144(11): 4980 - 4990. [Abstract] [Full Text] [PDF]

				S. Ramaswamy, G. R. Marshall, C. R. Pohl, R. L. Friedman, and T. M. Plant Inhibitory and Stimulatory Regulation of Testicular Inhibin B Secretion by Luteinizing Hormone and Follicle-Stimulating Hormone, Respectively, in the Rhesus Monkey (Macaca mulatta) Endocrinology, April 1, 2003; 144(4): 1175 - 1185. [Abstract] [Full Text] [PDF]

				K. L. Matthiesson, D. M. Robertson, H. G. Burger, and R. I. McLachlan Response of serum inhibin B and pro-{alpha}C levels to gonadotrophic stimulation in normal men before and after steroidal contraceptive treatment Hum. Reprod., April 1, 2003; 18(4): 734 - 743. [Abstract] [Full Text] [PDF]

				C. Marchetti, M. Hamdane, V. Mitchell, K. Mayo, L. Devisme, J.M. Rigot, J.C. Beauvillain, E. Hermand, and A. Defossez Immunolocalization of Inhibin and Activin {alpha} and {beta}B Subunits and Expression of Corresponding Messenger RNAs in the Human Adult Testis Biol Reprod, January 1, 2003; 68(1): 230 - 235. [Abstract] [Full Text] [PDF]

				C. Welt, Y. Sidis, H. Keutmann, and A. Schneyer Activins, Inhibins, and Follistatins: From Endocrinology to Signaling. A Paradigm for the New Millennium Experimental Biology and Medicine, October 1, 2002; 227(9): 724 - 752. [Abstract] [Full Text] [PDF]

				J. M. Kuhn, H. Lefebvre, C. Duparc, A. Pellerin, J. P. Luton, and G. Strauch Cosecretion of Estrogen and Inhibin B by a Feminizing Adrenocortical Adenoma: Impact on Gonadotropin Secretion J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2367 - 2375. [Abstract] [Full Text] [PDF]

				T. M. Plant and G. R. Marshall The Functional Significance of FSH in Spermatogenesis and the Control of Its Secretion in Male Primates Endocr. Rev., December 1, 2001; 22(6): 764 - 786. [Abstract] [Full Text] [PDF]